Report

Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.

Asset 41 2
160 1608792 circle document icon png transparent png

Asia-Pacific Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Long Acting Insulin, Rapid Acting Insulins, Short acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-like peptide-1 (GLP-1), Pens and Needles, and Others)   

The insulin market in APAC is expected to grow from US$ 7,288.17 million in 2022 to US$ 14,936.00 million by 2028. It is estimated to grow at a CAGR of 12.7% from 2022 to 2028.

Regeneration of Artificial Pancreas with Advanced Transplants to Emerge as Significant Therapeutic Trend

Body cells naturally produce small molecules, hormones, and proteins to keep the body functioning properly. The artificial pancreas can control blood sugar levels for people with type 1 diabetes better than the standard treatment. In people with type 1 diabetes, continuous glucose monitoring (CGM) devices provide around-the-clock information on blood glucose levels, which is used to determine the need/dosage of insulin. Insulin pumps allow the subcutaneous administration of insulin doses throughout the day. Despite frequent monitoring of blood sugar levels and dose adjustments, insulin injections do not ideally recreate the natural waves of insulin released from the pancreas. This leaves patients continually working to avoid chronically high or low blood sugar, which can cause blindness, diabetic coma, or life-threatening insulin shock. Various research groups have been working on technologies for regenerating pancreatic cells. These technologies are expected to prove promising for addressing the conditions associated with diabetes in the coming years .

Market Overview

Asia Pacific (APAC) is the fastest-growing market for insulins. The market in APAC is subsegmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. The growing prevalence of diabetes and rising incidence rates of lifestyle-related disorders such as obesity drive the market growth in the region. Several market players are focusing on countries in Asia Pacific for geographic expansion and other strategies. Therefore, the region holds a huge potential for insulin market players. The demand for insulin in China has increased in the past decade. According to PharmExec, China has ~114.4 million diabetic patients. The diabetes market in the country is predicted to reach US$ 6.67 billion in 2022. While other drugs such as DPP-4 inhibitors and GLP-1 agonists are available, insulins remain the country’s most commonly used antidiabetic drug. Insulin therapy is the primary treatment for people with type 1 diabetes, as pancreas stops synthesizing the hormone that regulates the body’s blood sugar levels. Some people with type 2 diabetes or gestational diabetes need to take insulin when other medications cannot keep blood sugar levels within the desired range. According to Statista, the market volume of human insulin and its analogs in China stood at ~US$ 2.96 billion in 2018, and it is expected to grow at an annual rate of 4.4% through 2030.

APAC Insulin Market Revenue and Forecast to 2028 (US$ Million)

APAC Insulin Market Segmentation

The APAC insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.

Based on long acting insulin, the APAC insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.

Based on short acting insulin and traditional human insulin, the APAC insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.

Based on concentrated insulin and combination insulin, the APAC insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022.

Based on biosimilar insulin, the APAC insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022.

Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China dominated the market share in 2022.

Adocia; Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Insulin Market – By Type
1.3.2 APAC Insulin Market – By Country
2. APAC Insulin Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Insulin Market – Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.2.1 Expert Opinion
5. APAC Insulin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market– APAC Analysis
6.1 APAC Insulin Market Revenue Forecast and Analysis
7. APAC Insulin Market Analysis – By Type
7.1 Overview
7.2 APAC Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8. APAC Insulin Market – Country Analysis
8.1 Overview
8.1.1 Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
8.1.1.1 China: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.1 China: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.2 China: Insulin Market, by Type, 2019–2028 (US$ Million)
8.1.1.1.2.1 China: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.2 China: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.3 China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.4 China: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.5 China: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.2 Japan: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.1 Japan: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.2 Japan: Insulin Market, by Type, 2019–2028 (US$ Million)
8.1.1.2.2.1 Japan: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.2 Japan: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.3 Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.4 Japan: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.5 Japan: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.3 India: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.1 India: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.2 India: Insulin Market, by Type, 2019–2028 (US$ Million)
8.1.1.3.2.1 India: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.2 India: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.3 India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.4 India: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.5 India: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.4 Australia: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.4.1 Australia: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.4.2 Australia: Insulin Market, by Type, 2019–2028 (US$ Million)
8.1.1.4.2.1 Australia: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.4.2.2 Australia: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.3 Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.4 Australia: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.5 Australia: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.5 South Korea: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.5.1 South Korea: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.5.2 South Korea: Insulin Market, by Type, 2019–2028 (US$ Million)
8.1.1.5.2.1 South Korea: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.5.2.2 South Korea: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.1.1.5.2.3 South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.5.2.4 South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.5.2.5 South Korea: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.6 Rest of Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.6.1 Rest of Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.6.2 Rest of Asia Pacific: Insulin Market, by Type, 2019–2028 (US$ Million)
8.1.1.6.2.1 Rest of Asia Pacific: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.6.2.2 Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.1.1.6.2.3 Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.6.2.4 Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.6.2.5 Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
9. APAC Insulin Market–Industry Landscape
9.1 Overview
9.2 Organic Developments
9.2.1 Overview
9.3 Inorganic Developments
9.3.1 Overview
10. Company Profile
10.1 Eli Lilly and Company
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Novo Nordisk A/S
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Biocon
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Wockhardt
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Adocia
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 GlaxoSmithKline plc.
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Sanofi
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Pfizer Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Merck & Co., Inc.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Products and Services
10.10.4 Financial Overview
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms

LIST OF TABLES

Table 1. APAC Insulin Market, Revenue and Forecast, 2019–2028 (US$ Million)
Table 2. China: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. China: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 4. China: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 5. China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 6. China: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 7. China: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 8. Japan: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Japan: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 10. Japan: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 11. Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 12. Japan: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 13. Japan: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 14. India: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. India: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 16. India: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 17. India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 18. India: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 19. India: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 20. Australia: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 21. Australia: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 22. Australia: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 23. Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 24. Australia: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 25. Australia: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 26. South Korea: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 27. South Korea: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 28. South Korea: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 29. South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 30. South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 31. South Korea: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 32. Rest of Asia Pacific: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 33. Rest of Asia Pacific: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 34. Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 35. Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028  (US$ Million)
Table 36. Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 37. Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 38. Organic Developments in the Insulin Market
Table 39. Inorganic Developments in the Insulin Market
Table 40. Glossary of Terms, Insulin Market
 
 

LIST OF FIGURES

Figure 1. APAC Insulin Market Segmentation
Figure 2. APAC Insulin Market Segmentation, By Country
Figure 3. APAC Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Asia-Pacific Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. Asia Pacific PEST Analysis
Figure 8. Expert Opinion
Figure 9. APAC Insulin Market Impact Analysis of Drivers and Restraints
Figure 10. APAC Insulin Market– Revenue Forecast and Analysis
Figure 11. APAC Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 12. APAC Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. APAC Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. APAC Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. APAC Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. APAC Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. APAC Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. APAC Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. APAC Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. APAC Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. APAC Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. APAC Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. APAC Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. APAC Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. APAC Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. APAC Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. APAC Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. APAC NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. APAC Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. APAC Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. APAC Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. APAC Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. APAC Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. APAC Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. APAC Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. APAC Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. APAC Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Asia Pacific: Insulin Market, by Key Country – Revenue (2021) (US$ Million)
Figure 39. Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
Figure 40. China: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Japan: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. India: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Australia: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. South Korea: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Rest of Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC insulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the APAC insulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

The List of Companies – Asia-Pacific Insulin Market

● Adocia
● Biocon
● Eli Lilly and Company
● GlaxoSmithKline plc.
● Merck & Co., Inc.
● Novo Nordisk A/S
● Pfizer Inc.
● Sanofi
● Tonghua Dongbao Pharmaceutical Co., Ltd.
● Wockhardt

Pricing

$3,000.00$5,000.00

Have a Query?

Have a Question?

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

GET FREE SAMPLE PDF

× Enquire Now